| Website | en.sanofi-aventis... |
| Category | BioTech |
| Phone | 33 (0)1 53 77 40 00 |
| Employees | |
| Founded | 2004 |
| Description | Drug Development |
| Total | $25.9B |
| Genzyme, 2/11 | $20B |
| TargeGen, 6/10 | $635M |
| Shantha Biotechnics, 7/09 | $770M |
| Merial Limited, 7/09 | $4B |
| BiPar Sciences, 4/09 | $500M |
| Rib-X Pharmaceuticals | 2/12 |
| Warp Drive Bio | 1/12 |
| Regulus Therapeutics | 10/10 |
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2008, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases.